BOSTON & SAN DIEGO–(BUSINESS WIRE)– #CCTA–Elucid, an innovator of AI-powered cardiovascular imaging software, today announced results from ELUCIDATE, presented at the annual Transcatheter Cardiovascular Therapeutics Conference (TCT 2026). The ELUCIDATE study, which supported Elucid’s recent U.S. Food and Drug Administration (FDA) 510(k) clearance of the FFR-IQTM software, demonstrated 92.9 percent vessel-level diagnostic accuracy for Elucid’s FFR-IQ technology versus invasive fractional flow reserve
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
